Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
Dexcom announced that the G7 15 Day CGM system will launch in Canada in November for adults 18 and older living with type 1 and type 2 diabetes. The sensor offers up to 15.5 days of wear with an overall MARD of 8.0%, which the company describes as the longest-lasting and most accurate CGM authorized by Health Canada. Public reimbursement for many eligible Canadians and coverage from most private CGM-covering plans begin in November, and Dexcom expects automated insulin delivery integration to follow shortly.
Key figures
- Mard
- 8.0%
- Launch market
- Canada
- Launch timing
- November
- Wear duration
- up to 15.5 days
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.